Next Pick
Earnings DeskOpen the stock page →

Ultragenyx Pharmaceutical Inc. · Biotechnology

RAREUltragenyx Pharmaceutical Inc.

Reports 2026-11-03 After close · TueReaction day 11-04reported · reaction in progress

Before the print · expectationsfrozen at T-1

No past prints on file yet.

What the record doesn't tell you

Which way does RARE go on 11‑03?

  • Model lean for 11-03, and the evidence behind it
  • Move band, P10 – P90
  • Last 8 prints, quarter by quarter
  • Peers that already reported, and how they traded
Start 30-day free trialFull access · no card requiredHave an account? Sign in

The print · 8-K and call2026-11-03 · After close

Revenue$173M
est. —
EPS—
est. —
Guidance · FY revenue$730.0M–$760.0M
vs consensus −2.0% · Consensus $760.2M

Key figures, the focus-point check, management quotes, the sector read and the grade are in the full view. Start 30-day free trial →

Reactionreaction not yet settled

After-hours move—no read yet
Open / day close— / —
5 days later—day 5 pending

Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →

Ultragenyx Pharmaceutical earnings review: what the record says

Ultragenyx Pharmaceutical (RARE) reported earnings on Nov 3, 2026, after the close. The company posted revenue of $173M.

Figures come from NextPick's earnings-reaction ledger and the options market. Not investment advice.